M&A Deal Summary

Lantheus Medical Imaging Acquires Cerveau Technologies

On February 6, 2023, Lantheus Medical Imaging acquired information technology company Cerveau Technologies

Acquisition Highlights
  • This is Lantheus Medical Imaging’s 1st transaction in the Information Technology sector.
  • This is Lantheus Medical Imaging’s 2nd transaction in the United States.
  • This is Lantheus Medical Imaging’s 1st transaction in Texas.

M&A Deal Summary

Date 2023-02-06
Target Cerveau Technologies
Sector Information Technology
Buyer(s) Lantheus Medical Imaging
Deal Type Add-on Acquisition
Advisor(s) Chestnut Partners (Financial)

Target

Cerveau Technologies

Knoxville, Texas, United States
Cerveau Technologies is a provider of information and technology to researchers and clinicians in order to improve brain health. Cerveau Technologies is based in Knoxville, Texas.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Lantheus Medical Imaging

Bedford, Massachusetts, United States

Category Company
Founded 1956
Sector Medical Products
Employees808
Revenue 1.5B USD (2024)
DESCRIPTION

Lantheus Medical Imaging is a supplier of radiopharmaceuticals and contrast agents for nuclear and ultrasound-based cardiovascular diagnostic imaging procedures. Lantheus Medical Imaging was founded in 1956 and is based in Bedford, Massachusetts.


DEAL STATS #
Overall 2 of 5
Sector: Information Technology M&A 1 of 1
Type: Add-on Acquisition M&A Deals 2 of 4
State: Texas M&A 1 of 1
Country: United States M&A 2 of 4
Year: 2023 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-12-03 Lantheus Puerto Rico Radiopharmacy and PET Manufacturing Facility

San Juan, Puerto Rico

Lantheus' Puerto Rico Radiopharmacy and PET Manufacturing Facility include both the Lantheus radiopharmacy and PMF businesses located in San Juan, Puerto Rico. The radiopharmacy prepares individual, patient-ready doses of radiopharmaceuticals, and the PMF manufactures the drug product for individual, patient-ready doses of fluorodeoxyglucose (FDG).

Sell $18M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-07-15 Meilleur

Dublin, Ohio, United States

Meilleur is a provider of imaging biomarkers for neurological pathologies, associated information technology and related tools to accelerate the development, approval, and adoption of effective therapies to treat neurodegenerative diseases. Meilleur is based in Dublin, Ohio.

Buy -